Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

PR Newswire February 3, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

PR Newswire January 19, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021

PR Newswire November 18, 2021

ESSA Pharma to Participate in Three Upcoming Investor Conferences

PR Newswire November 8, 2021

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 28, 2021

ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386

PR Newswire October 7, 2021

Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration

PR Newswire October 7, 2021

ESSA Pharma to Present at Upcoming September Investor Conferences

PR Newswire August 31, 2021

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021

PR Newswire August 16, 2021

ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

PR Newswire May 25, 2021

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

Canada NewsWire May 6, 2021

ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

PR Newswire April 28, 2021

ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 14, 2021

ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

Canada NewsWire April 10, 2021

ESSA Announces Change to its Board of Directors

Canada NewsWire March 26, 2021

ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

Canada NewsWire March 4, 2021

LAWSUIT FILED: Ebix, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

ACCESSWIRE IA March 2, 2021

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

Canada NewsWire February 25, 2021

ESSA Pharma to Present at Upcoming March Investor Conferences

Canada NewsWire February 25, 2021

ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Canada NewsWire February 25, 2021